UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$278M |
| 2 |
United Rentals
URI
|
+$213M |
| 3 |
Affiliated Managers Group
AMG
|
+$189M |
| 4 |
Yelp
YELP
|
+$146M |
| 5 |
Microsoft
MSFT
|
+$145M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$223M |
| 2 |
RTX Corp
RTX
|
+$188M |
| 3 |
AGN
Allergan Inc
AGN
|
+$184M |
| 4 |
Crown Castle
CCI
|
+$171M |
| 5 |
Mastercard
MA
|
+$128M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.34% |
| 2 | Technology | 14.73% |
| 3 | Financials | 14.56% |
| 4 | Consumer Discretionary | 9.63% |
| 5 | Industrials | 8.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CCMP
2026
DELISTED
CMC Materials, Inc. Common Stock
CCMP
| $383K | ﹤0.01% |
8,100
| – | – |
|
|
AMED
2027
DELISTED
Amedisys
AMED
| $382K | ﹤0.01% |
12,999
| – | – |
|
2028
Zumiez
ZUMZ
$332M
| $382K | ﹤0.01% |
9,899
| – | – |
|
2029
RPC Inc
RES
$1.31B
| $381K | ﹤0.01% |
29,198
+4,000
| +16% | +$61.6K |
|
2030
Insperity
NSP
$1.96B
| $380K | ﹤0.01% |
22,398
+2,400
| +12% | +$37.9K |
|
|
AVX
2031
DELISTED
AVX Corporation
AVX
| $379K | ﹤0.01% |
27,096
+2,800
| +12% | +$38.6K |
|
|
ELLI
2032
DELISTED
Ellie Mae Inc
ELLI
| $379K | ﹤0.01% |
9,400
+1,000
| +12% | +$38.7K |
|
2033
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$719M
| – | – |
0
| – | – |
|
|
CBM
2034
DELISTED
Cambrex Corporation
CBM
| $378K | ﹤0.01% |
+17,499
| New | +$371K |
|
|
BLT
2035
DELISTED
BLOUNT INTERNATIONAL (NEW)
BLT
| $378K | ﹤0.01% |
21,498
+2,500
| +13% | +$40K |
|
2036
Hanmi Financial
HAFC
$954M
| $376K | ﹤0.01% |
17,232
+2,000
| +13% | +$41.6K |
|
|
RP
2037
DELISTED
RealPage, Inc.
RP
| $375K | ﹤0.01% |
17,099
+2,000
| +13% | +$39.6K |
|
2038
HSBC
HSBC
$352B
| $374K | ﹤0.01% |
9,195
-560
| -6% | -$23.9K |
|
|
CIR
2039
DELISTED
CIRCOR International, Inc
CIR
| $374K | ﹤0.01% |
6,200
-35,752
| -85% | -$2.35M |
|
|
INFI
2040
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $374K | ﹤0.01% |
22,119
+2,400
| +12% | +$34.9K |
|
|
ARI
2041
Apollo Commercial Real Estate
ARI
$876M
| $373K | ﹤0.01% |
22,798
+500
| +2% | +$8.21K |
|
|
KG
2042
Kestrel Group
KG
$69.7M
| $373K | ﹤0.01% |
1,460
+170
| +13% | +$42.1K |
|
2043
Churchill Downs
CHDN
$6.06B
| $372K | ﹤0.01% |
23,400
| – | – |
|
2044
Chesapeake Utilities
CPK
$3.2B
| $372K | ﹤0.01% |
7,500
| – | – |
|
2045
Ethan Allen Interiors
ETD
$598M
| $372K | ﹤0.01% |
11,999
| – | – |
|
|
TBI
2046
Trueblue
TBI
$310M
| $372K | ﹤0.01% |
16,699
| – | – |
|
2047
Halozyme
HALO
$10.2B
| $371K | ﹤0.01% |
38,396
+3,600
| +10% | +$32K |
|
|
ANAC
2048
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $371K | ﹤0.01% |
11,500
+1,300
| +13% | +$39K |
|
2049
8x8 Inc
EGHT
$327M
| $370K | ﹤0.01% |
40,351
+5,400
| +15% | +$41.4K |
|
2050
iShares MSCI Switzerland ETF
EWL
$2.21B
| $369K | ﹤0.01% |
11,629
-3,432
| -23% | -$110K |
|
Similar funds
UBS AM's Q4 2014 Portfolio in Review
As of Q4 2014, UBS AM held 2,689 positions worth $105B, up 4.2% from $101B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
UBS AM's Q4 2014 filing shows 129 new, 1,370 increased, 628 reduced and 77 closed positions. Its largest new stake was Restaurant Brands International: 383,271 shares worth $15.1M. The largest sale was Biogen, an estimated $223M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
- UBS AM's largest Q4 2014 buy was Restaurant Brands International: 383,271 shares worth $15.1M.
- UBS AM added most to Celgene Corp in Q4 2014, an estimated $278M increase.
- UBS AM's biggest Q4 2014 reduction was Biogen, cutting an estimated $223M.
- UBS AM fully exited KINDER MORGAN MANAGEMENT LLC in Q4 2014, selling an estimated $45.3M.
- UBS AM's ten largest holdings make up 14% of its $105B portfolio in Q4 2014.
- UBS AM opened 129 new positions and closed 77 in Q4 2014.
- UBS AM's portfolio value rose 4.2% quarter-over-quarter to $105B.
Based on UBS AM's 13F filing for Q4 2014, filed 2 Feb 2015.